On April 2, 2026, the White House announced a new pharmaceutical tariff framework that would apply to certain imported patented prescription drugs and select active pharmaceutical ingredients. The concern is less about trade policy but more about what could change in pharmacy spend, formulary dynamics, and drug availability as the policy rolls out.
While the headline tariff rate is 100% for covered products, the policy includes a phased start date and several exception pathways that may limit near term disruption. The announcement was made under Section 232, which gives the federal government authority to impose import restrictions after a Commerce Department review. Under the framework described in federal materials, implementation begins 120 days after the announcement for certain large manufacturers and 180 days after the announcement for smaller manufacturers and other importers, with generic drugs and biosimilars currently excluded.
Below is a high level summary of what has been announced so far, how it differs from earlier tariff signals in 2025, and what can be monitored more details emerge.
What was announced on April 2, 2026
Scope, applicability, and exemptions
Currently, the pharmaceutical tariffs only apply to patented brand name drugs and certain active pharmaceutical ingredients (APIs). Generic drugs and biosimilars, along with their associated ingredients, are exempt at this time, although the administration indicated it will reassess that approach within 1 year. The new pharmaceutical tariffs also outline exceptions for specific orphan drugs and some specialty products that address urgent public health needs, as long as they meet public health standards or are from countries with trade agreements.
Country based tariff rates
Pharmaceutical products imported from the European Union, Japan, South Korea, Switzerland, and Liechtenstein are subject to a 15% tariff rate under the current trade agreement. The United Kingdom is effectively exempt, thanks to a recently finalized pharmaceutical trade agreement. Countries without trade agreements face the headline 100% tariff rate, absent other mitigation.
Reduced or avoided tariffs via compliance
The pharmaceutical tariffs also outline reduced rate pathways through January 20, 2029, tied to pharma manufacturer company commitments. There is 0% tariff rate for that enter into both Most Favored Nation pricing agreements with the U.S. Department of Health and Human Services (HHS) and onshoring agreements with the Department of Commerce. For companies that enter into onshoring agreements with only the Department of Commerce, there is a 20% tariff rate through January 20, 2029.
How this differs from 2025
In September 2025, federal officials signaled a potential 100% tariff on imported brand name pharmaceuticals, which created uncertainty across manufacturers and the pharmacy supply chain. The April 2026 framework is more defined, with a phased start date, clearer exemptions, and described reduced rate pathways tied to company commitments. For employer sponsored plans, that shift matters because it can concentrate exposure in specific drug categories rather than driving immediate, broad changes across the entire benefit.
Expected Impact of Pharma Tariffs
Drug Pricing
Immediate, broad-based price increases from the pharmaceutical tariffs are unlikely in the near term due to existing exemptions, gradual implementation timelines, and available exception pathways. Over time, however, the pharmaceutical tariffs could create upward pricing pressure for certain imported specialty and patented drugs, particularly those manufactured outside countries covered by trade agreements or not aligned with Most Favored Nation pricing frameworks. While generics remain unaffected today, any future expansion of pharmaceutical tariff policy to include generics would have significant downstream cost implications, given that generic drugs account for roughly 90% of all U.S. prescriptions.
Supply Chain
PBMs may reassess formularies based on country of manufacture exposure, margin sensitivity, and supply risk. As some manufacturers shift production onshore, plans could see short term supply disruptions, particularly for complex specialty and biologic therapies.
What this signals for pharmacy benefits
Even with exemptions and a phased timeline, the April 2026 framework underscores a broader shift: federal trade policy and manufacturing location can increasingly influence the pharmacy benefit, not just through list prices, but through availability, contracting leverage, and formulary decision making.
- Expect uneven impact, not uniform inflation: Exposure will likely cluster in select imported patented and specialty drugs rather than across the full formulary.
- Transparency becomes more valuable: Country of manufacture and supply chain concentration can affect risk, but those details are not always visible in standard plan reporting.
- PBM decision making may move faster: If sourcing affects net cost, PBMs may reassess preferred products and implement formulary changes with more frequency.
- Contract terms matter: Market change provisions, notice requirements, and governance for formulary updates can determine how much control employers retain during disruption.
- Reassessment risk remains: Current materials exempt generics and biosimilars, but they also note potential reassessment within 1 year, which would materially expand plan exposure.
As pharmaceutical tariffs continue to take shape, employers and benefits consultants will need to stay focused on where exposure may concentrate rather than assuming across-the-board disruption. Monitoring formulary changes, understanding contract protections, and maintaining regular dialogue with PBMs can help plans respond thoughtfully as details evolve. While the current framework limits immediate impact, pharmaceutical tariffs remain a policy lever worth watching closely as pricing, sourcing, and manufacturing strategies continue to shift.
Truveris is a leading digital health company focused on delivering truth and clarity in pharmacy. Truveris’ proprietary technology, coupled with deep pharmacy expertise, helps to build a more efficient market that maximizes choice, accessibility, and prescription drug affordability. Our solutions provide the insight and knowledge to help people lead healthier and more productive lives.
